Hospira is voluntarily recalling three lots of the injectable opioid medication Hydromorphone HCl because the glass vials may be broken or cracked, the Food and Drug Administration announced yesterday. Hospira has notified hospitals and others with an existing inventory of the lots subject to this recall that they should stop use and distribution of the remaining units and quarantine them immediately. See the FDA announcement for more information, including the lot numbers. Health care professionals are encouraged to report any related problems or events to the FDA's MedWatch Program. Last week, the AHA and others asked the Drug Enforcement Administration to temporarily adjust the aggregate production quotas for certain injectable opioid medications in short supply to allow other manufacturers to supply product until the shortages resolve.
 

Related News Articles

Headline
The Centers for Disease Control and Prevention today activated its Emergency Operations Center to support the interagency response to the Ebola outbreak in…
Headline
The World Health Organization has confirmed the first cases of Ebola in Uganda since 2013.
Blog
In this AHA Stat blog, Institute for Diversity and Health Equity President and CEO Duane Reynolds highlights various resources, programs and efforts to help…
Headline
President Trump yesterday signed legislation providing $19.1 billion in disaster relief for areas affected by hurricanes, wildfires and other recent natural…
Headline
The Centers for Disease Control and Prevention this week announced an anticipated shortage of Aplisol, one of two TB skin tests licensed by the Food and Drug…
Headline
The Centers for Disease Control and Prevention yesterday reported 1,001 cases of measles so far this year, according to the Department of Health and Human…